A Study of SGN-ALPV in Advanced Solid Tumors
- Conditions
- Ovarian NeoplasmsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungStomach NeoplasmsGastroesophageal Junction CarcinomaUterine Cervical NeoplasmsTesticular Neoplasms
- Interventions
- Registration Number
- NCT05229900
- Lead Sponsor
- Seagen Inc.
- Brief Summary
This study will test the safety of a drug called SGN-ALPV in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease.
Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
This study will have three parts. Parts A and B of the study will find out how much SGN-ALPV should be given to participants. Part C will use the dose and schedule found in Parts A and B to find out how safe SGN-ALPV is and if it works to treat solid tumor cancers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 43
-
Participants must have one of the following histologically or cytologically confirmed metastatic or unresectable solid tumor types:
-
Parts A and B
- Ovarian cancer
- Endometrial cancer
- Non-small cell lung cancer (NSCLC)
- Gastric cancer, including gastroesophageal junction (GEJ) carcinoma
- Cervical cancer
- Malignant testicular germ cell tumor (GCT), except for pure teratomas
- Malignant ovarian GCT, except for pure teratomas
- Malignant extragonadal GCT except for pure teratomas or tumors with primaries arising from CNS
-
Part C
- High-grade serous ovarian cancer (HGSOC): Participants must have HGSOC which has progressed or relapsed within 6 months after previous platinum containing chemotherapy, received 2 to 4 prior anticancer lines of therapy, and at least 1 line of therapy in the platinum-resistant setting. If eligible at least 1 line of therapy must have contained bevacizumab or a biosimilar to bevacizumab.
- Endometrial Cancer: Participants must have unresectable locally advance or metastatic endometrial carcinoma and have had at least 1 prior line of therapy.
- NSCLC: Participants must have unresectable locally advanced or metastatic NSCLC and have received platinum-based therapy and a PD-(L)1 inhibitor.
- Gastric cancer or GEJ carcinoma: Participants must have unresectable locally advanced or metastatic gastric cancer or GEJ carcinoma and have received prior platinum and fluoropyrimidine -based chemotherapy
-
-
Participants enrolled in the following study parts should have an appropriate tumor site and agree to a biopsy
- Part B dose and schedule optimization cohorts and Part C disease-specific expansion cohorts: pretreatment biopsy, unless clinically infeasible following consultation with the medical monitor.
- Part C biology expansion cohort: pretreatment biopsy (required), on-treatment biopsy during Cycle 1 (unless clinically infeasible following consultation with the medical monitor)
-
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
-
Measurable disease per the RECIST v1.1 at baseline
- History of another malignancy within 3 years of first dose of study treatment or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
- Known active central nervous system metastases.
- Previous receipt of an MMAE-containing agent or an agent targeting ALPP or ALPPL2.
- Pre-existing neuropathy ≥ Grade 2 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description SGN-ALPV SGN-ALPV SGN-ALPV monotherapy
- Primary Outcome Measures
Name Time Method Number of participants with adverse events (AEs) Through 30-37 days after last study treatment, approximately 6 months Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Number of participants with laboratory abnormalities Through 30-37 days after last study treatment, approximately 6 months Number of participants with dose-limiting toxicities (DLTs) Up to 28 days Number of participants with DLTs by dose level Up to 28 days
- Secondary Outcome Measures
Name Time Method Area under the concentration-time curve (AUC) Through 14 days after last study treatment, approximately 6 months PK parameter
Incidence of antidrug antibodies (ADAs) Through 30-37 days after last study treatment, approximately 6 months Maximum concentration (Cmax) Through 14 days after last study treatment, approximately 6 months PK parameter
Time to Cmax (Tmax) Through 14 days after last study treatment, approximately 6 months PK parameter
Apparent terminal half-life (t1/2) Through 14 days after last study treatment, approximately 6 months PK parameter
Trough concentration (Ctrough) Through 14 days after last study treatment, approximately 6 months PK parameter
Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Approximately 2 years The proportion of participants with an objective response (OR) per investigator. A participant is determined to have an OR if, based on RECIST v1.1, the subject achieves a complete response (CR) or a partial response (PR) after initiation of treatment and at or prior to the end of treatment (EOT) disease assessment.
Duration of objective response (DOR) Approximately 2 years The time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression (based on radiographic assessments per RECIST v1.1) or death due to any cause.
Progression-free survival (PFS) Approximately 2 years The time from start of study treatment to first documentation of disease progression or death due to any cause
Overall survival (OS) Approximately 2 years The time from start of study treatment to death due to any cause
CA-125 response rate according to Gynecological Cancer Intergroup (GCIG) criteria (subjects with ovarian cancer only) Approximately 2 years The proportion of participants with ovarian cancer who have at least a 50% reduction in CA-125 value from baseline according to GCIG CA-125 criteria
Combined RECIST/CA-125 overall response rate according to GCIG (subjects with ovarian cancer only) Approximately 2 years The proportion of participants with ovarian cancer whose best response is a CR or PR according to the GCIG combined RECIST and CA-125 criteria
Trial Locations
- Locations (13)
Women's Cancer Care
🇺🇸Fresno, California, United States
Virginia Cancer Specialists
🇺🇸Fairfax, Virginia, United States
University Health Network, Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada
Ottawa Hospital Cancer Centre
🇨🇦Ottawa, Ontario, Canada
Karolinska University Hospital
🇸🇪Stockholm, Other, Sweden
START Madrid-CIOCC_Hospital HM Sanchinarro
🇪🇸Madrid, Other, Spain
START Mountain Region
🇺🇸West Valley City, Utah, United States
Oklahoma University at Stephenson Cancer Center
🇺🇸Oklahoma City, Oklahoma, United States
Florida Cancer Specialists - Lake Nona
🇺🇸Wellington, Florida, United States
START Midwest
🇺🇸Grand Rapids, Michigan, United States
The Royal Marsden NHS Foundation Trust (RM)
🇬🇧London, Other, United Kingdom
Sarah Cannon Research Institute UK
🇬🇧London, Other, United Kingdom
Yale Cancer Center
🇺🇸New Haven, Connecticut, United States